专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08486891B2 Nasal calcitonin formulations containing chlorobutanol 有权
标题翻译：包含氯丁醇的鼻降钙素制剂
公开(公告)号：US08486891B2
公开(公告)日：2013-07-16
申请号：US13371037
申请日：2012-02-10
申请人： Steven C. Quay , Jorge C. de Meireles , Arati Deshpande , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Jorge C. de Meireles , Arati Deshpande , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61K38/23 , C07K14/585
CPC分类号： A61K9/0043 , A61K38/23
摘要： An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.
摘要翻译：适于鼻内给药的降钙素水溶液包含浓度小于0.4重量％的降钙素，氯丁醇和水，pH小于4，条件是溶液中不存在苯扎氯铵。降钙素水溶液可用于治疗骨质疏松症，佩吉特骨病和高钙血症。

12. 发明申请

US20110009321A1 NASAL CALCITONIN FORMULATIONS CONTAINING CHLOROBUTANOL 有权
标题翻译：包含氯丁醇的纳卡尔钙钙配方
公开(公告)号：US20110009321A1
公开(公告)日：2011-01-13
申请号：US12878936
申请日：2010-09-09
申请人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61K38/23 , A61P19/10 , A61P19/08 , A61P3/00
CPC分类号： A61K9/0043 , A61K38/23
摘要： An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.
摘要翻译：适于鼻内给药的降钙素水溶液包含浓度小于0.4重量％的降钙素，氯丁醇和水，pH小于4，条件是溶液中不存在苯扎氯铵。降钙素水溶液可用于治疗骨质疏松症，佩吉特骨病和高钙血症。

13. 发明授权

US07812120B2 Nasal calcitonin formulations containing chlorobutanol 有权
标题翻译：包含氯丁醇的鼻降钙素制剂
公开(公告)号：US07812120B2
公开(公告)日：2010-10-12
申请号：US10805788
申请日：2004-03-22
申请人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61K38/00
CPC分类号： A61K9/0043 , A61K38/23
摘要： Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof.
摘要翻译：适合鼻内给药的组合物含有降钙素，氯丁醇，pH值约为3.5，氯化钠，鼻内喷雾剂及药物输送装置。

14. 发明申请

US20100209487A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF 有权
标题翻译：粘结或加入的核酸分子及其用途
公开(公告)号：US20100209487A1
公开(公告)日：2010-08-19
申请号：US12445868
申请日：2007-10-18
申请人： Steven C. Quay , James Mcswiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James Mcswiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： A61K31/713 , C07H21/02 , A61K9/127 , A61K9/51 , C12N5/071 , A61P35/00 , A61P29/00 , A61P31/00
CPC分类号： A61K31/713 , A61K38/00 , A61K47/645 , A61K47/66 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/15 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3513 , C12N2310/533 , C12N2320/30 , C12N2320/51 , C12N2330/30 , C12N2310/3521
摘要： The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
摘要翻译：本公开提供降低或沉默靶基因表达的meroduplex（切口或间隙）核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙分开的至少两个非重叠的双链区域，其中一条链与靶基因RNA互补。此外，meroduplex可以具有一个或多个修饰或取代，例如核苷酸碱基，糖，末端帽结构，核苷酸间连接，或这些修饰的任何组合。还提供减少细胞或受试者中靶基因表达以治疗与靶基因表达改变相关的疾病的方法。

15. 发明申请

US20090018097A1 MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES 审中-公开
标题翻译：双链抗坏血酸分子的修饰
公开(公告)号：US20090018097A1
公开(公告)日：2009-01-15
申请号：US12065604
申请日：2006-05-25
申请人： Steven C. Quay , Kunyuan Cui , Paul H. Johnson , Lishan Chen , Mohammad Ahmadian
发明人： Steven C. Quay , Kunyuan Cui , Paul H. Johnson , Lishan Chen , Mohammad Ahmadian
IPC分类号： A61K31/713 , C07H21/02 , C12N5/10 , A61P35/00
CPC分类号： C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2320/50 , C12N2320/51 , C12N2310/3521
摘要： A double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5′-methyl-pyrimidine and/or at least one 2′-O-methyl ribonucleotide, and a method of improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA.
摘要翻译：包含约15个碱基对和约40个碱基对的双链RNA（dsRNA）分子，其中dsRNA的至少一个核糖核苷酸是5'-甲基 - 嘧啶和/或至少一个2'-O-甲基核糖核苷酸，以及使用这种dsRNA，提高核糖核酸酶稳定性，降低双链siRNA分子的脱靶效应或降低双链siRNA分子的干扰素反应性的方法。

16. 发明申请

US20080286866A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制VEGF基因表达的核酸化合物及其用途
公开(公告)号：US20080286866A1
公开(公告)日：2008-11-20
申请号：US12039650
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/06 , C07H21/02
CPC分类号： C12N15/1136 , C12N2310/14
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing VEGFA, VEGFB, VEGFC, FIGF, or PGF gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a VEGF mRNA. In addition, the meroduplex may have at least one 5-methyluridine, locked nucleic acid, 2′-O-methyl, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a VEGF gene in a cell or in a subject to treat a VEGF-related disease.
摘要翻译：本公开提供能够降低或沉默VEGFA，VEGFB，VEGFC，FIGF或PGF基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个不重叠的双链区域，其中一条链与VEGF mRNA互补。此外，meroduplex可以具有至少一个5-甲基尿苷，锁定核酸，2'-O-甲基或任选的其它修饰及其任何组合。还提供减少细胞或受试者中VEGF基因表达以治疗VEGF相关疾病的方法。

17. 发明申请

US20080182817A1 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery 有权
标题翻译：用于鼻内给药的氰钴胺素低粘度含水制剂
公开(公告)号：US20080182817A1
公开(公告)日：2008-07-31
申请号：US12079875
申请日：2008-03-27
申请人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61K31/7056 , A61P43/00
CPC分类号： A61K9/0043 , A61K9/08 , A61K31/7056 , A61K31/714 , A61K47/10 , A61K47/12 , A61K47/186
摘要： A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.
摘要翻译：一种由氰钴胺素和水组成的稳定的药用无汞水溶液，其中所述氰钴胺溶液适合于鼻内给药，其粘度小于约1000cPs，其中所述氰钴胺溶液在鼻内给药时具有氰钴胺素的生物利用度相对于肌内注射氰钴胺素至少约7％，条件是溶液基本上不含汞和含汞化合物。本发明还涉及提高脑脊髓液（CSF）中维生素B12水平的方法，其包括向鼻内施用足够量的无汞氰钴胺溶液，以增加CSF中维生素B12的平均比例在血清中（B12 CSF / B12 Serumx100）至少约1.1，包括鼻内施用氰钴胺水溶液，其中所述氰钴胺溶液相对于肌内注射氰钴胺素具有至少7％的生物利用度。

18. 发明授权

US07329725B1 Phage displayed Trp cage ligands 有权
标题翻译：噬菌体展示Trp笼配体
公开(公告)号：US07329725B1
公开(公告)日：2008-02-12
申请号：US10976942
申请日：2004-10-29
申请人： Steven C. Quay , Douglas L. Badders , Richard E. Herman , Michael E. Houston, Jr. , Paul Hickok Johnson
发明人： Steven C. Quay , Douglas L. Badders , Richard E. Herman , Michael E. Houston, Jr. , Paul Hickok Johnson
IPC分类号： A61K38/00 , A61K38/26 , C12Q1/68 , C12N7/00 , C12N15/00
CPC分类号： C12N15/1037 , A61K38/00
摘要： Trp cage binding domain polypeptides are disclosed. The Trp cage binding domains have the generic formulas of SEQ ID NO: 2, 7, 10 or 11. They can be efficiently produced and screened using phage display technology.
摘要翻译：公开了Trp结构域结合域多肽。 Trp结构域具有SEQ ID NO：2，7，10或11的通式。它们可以使用噬菌体展示技术有效地生产和筛选。

19. 发明申请

US20070275923A1 CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY 审中-公开
标题翻译：用于siRNA细胞递送的阳离子肽
公开(公告)号：US20070275923A1
公开(公告)日：2007-11-29
申请号：US11676221
申请日：2007-02-16
申请人： Lishan Chen , Michael E. Houston , Roger C. Adami , James Anthony McSwiggen , Sasha J. Mayer , Steven C. Quay
发明人： Lishan Chen , Michael E. Houston , Roger C. Adami , James Anthony McSwiggen , Sasha J. Mayer , Steven C. Quay
IPC分类号： A61K31/7052 , C07H21/04 , C12N15/00 , C12N5/06
CPC分类号： C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/351 , C12N2310/3513 , C12N2320/32
摘要： What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L forms of arginine.
摘要翻译：描述了用于将RNA分子递送至细胞的组合物，其包含：约15至约40个碱基对的双链RNA（dsRNA）分子; 和多核苷酸递送增强肽，其包含交替的赖氨酸和组氨酸残基的区域，或交替的D和L形式的精氨酸。

20. 发明授权

US06894026B1 Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders 失效
标题翻译：长效催产素类似物用于治疗和预防乳腺癌和精神疾病
公开(公告)号：US06894026B1
公开(公告)日：2005-05-17
申请号：US09678591
申请日：2000-10-03
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K31/395 , A61K38/00
CPC分类号： A61K31/395
摘要： Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and/or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and/or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and/or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
摘要翻译：提供了用于预防和治疗乳腺癌的方法和组合物，其涉及施用治疗有效量的卡贝缩丁和/或其它长效催产素类似物。使用药学上可接受的载体配制1-丁酸-2-（O-甲基-L-酪氨酸）-1-氨基羰基（卡贝肝素）和/或其它长效催产素类似物，并以足以抑制起始或生长的量施用的乳腺癌患者。还可以用药学上可接受的载体配制卡贝缩丁酯和/或其它长效催产素类似物，并以足以治疗，预防或减轻患者精神障碍症状的量施用。卡培西可以预防性施用或通过各种施用方式治疗患者的现有病症，包括肌肉内，静脉内，鼻内，肺内，皮下，胃肠外，口服或透皮递送方法和制剂。优选地，通过鼻内递送将卡贝缩is物施用于患者的粘膜表面。为此目的，提供药物组合物用于鼻内递送，其中将卡贝缩胆胺掺入粉末或水性制剂用于鼻内递送。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式